-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QcDqNgj4xXXigtf0T8dBkM19EuvjDpDNwwjugtLQYMNFWzQBniuk1/9Cp8c5Jg7D ICYA6p5dHF8Ihkkx7e7jxg== 0001094328-03-000011.txt : 20030117 0001094328-03-000011.hdr.sgml : 20030117 20030117103615 ACCESSION NUMBER: 0001094328-03-000011 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030117 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: LEE LAWRENCE CENTRAL INDEX KEY: 0001208860 FILING VALUES: FORM TYPE: SC 13D MAIL ADDRESS: STREET 1: PO BOX 88715 CITY: LOS ANGELES STATE: CA ZIP: 90009 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: APPLIED DNA SCIENCES INC CENTRAL INDEX KEY: 0000744452 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 592262718 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-78682 FILM NUMBER: 03517136 BUSINESS ADDRESS: STREET 1: 211 WEST WALL CITY: MIDLAND STATE: TX ZIP: 79701 BUSINESS PHONE: 9156821761 MAIL ADDRESS: STREET 1: 211 WEST WALL CITY: MIDLAND STATE: TX ZIP: 79701 FORMER COMPANY: FORMER CONFORMED NAME: DATALINK SYSTEMS INC DATE OF NAME CHANGE: 19980306 FORMER COMPANY: FORMER CONFORMED NAME: DATALINK CAPITAL CORP/TX/ DATE OF NAME CHANGE: 19980306 FORMER COMPANY: FORMER CONFORMED NAME: DCC ACQUISITION CORP DATE OF NAME CHANGE: 19990211 FORMER COMPANY: FORMER CONFORMED NAME: PROHEALTH MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 20010504 SC 13D 1 lee23d011603.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 APPLIED DNA SCIENCES, INC. - --------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 - --------------------------------------------------------------------- (Title of Class of Securities) 03815U 10 2 - --------------------------------------------------------------------- (CUSIP Number) Lawrence "Larry" Lee (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 15, 2002 - ----------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box []. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP NO. 03815U 10 2 SCHEDULE 13D - ---------------------------- ---------------- CUSIP NO. 03815U 10 2 PAGE 2 OF 5 PAGES - ---------------------------- ---------------- - --------------------------------------------------------------------- - -- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Larry Lee n/a - ----------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (A) [ ] (B) [ ] - --------------------------------------------------------------------- 3 SEC USE ONLY - --------------------------------------------------------------------- 4 SOURCE OF FUNDS (See Instructions) - --------------------------------------------------------------------- 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) - --------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. - --------------------------------------------------------------------- 7 SOLE VOTING POWER 4,820,000 NUMBER OF ------------------------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY - 0 - EACH ----------------------------------------------------- REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH 4,820,000 ----------------------------------------------------- 10 SHARED DISPOSITIVE POWER - 0 - - --------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,820,000 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) [ ] - --------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 22.4% - --------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) IN - --------------------------------------------------------------------- ITEM 1. SECURITY AND ISSUER. This Statement relates to shares of common stock, $0.0001 par value per share (the "Common Stock"), of APPLIED DNA SCIENCES, INC. (the "Corporation"). The Corporation's principal executive office is located at 8233 Roxbury Road Los Angeles, CA 90069 ITEM 2. IDENTITY AND BACKGROUND. (a) This Statement is being filed by RHL Management, Inc. (the "Reporting Person"). (b) The business address of the Reporting Person is: 9225 West Sunset Blvd., Suite 805, Los Angeles, California 90096 (c) The Reporting Person's present principal occupation is: President (d) During the past five years, Mr. Lawrence Lee has not been convicted in a criminal proceeding. (e) During the last five years, Mr. Lee has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding been subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities law or finding any violation with respect to such law. (f) The Reporting Person is a citizen of the United States. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. The Reporting entity initially acquired a total of 5,500,000 shares of Common Stock of the Company in a Plan and Agreement of Reorganization between the shareholders of Applied DNA Sciences, Inc. (of which the reporting entity was one of two) and ProHealth Medical Technologies, Inc. After the reorganization, ProHealth Medical Technologies, Inc. was renamed Applied DNA Sciences, Inc. ITEM 4. PURPOSE OF TRANSACTION. The Reporting Person has acquired his beneficial ownership in the shares of Common Stock in a Reorganization classified under the I.R.C. as a 368(a)1(B) Plan and Agreement of Reorganization. The transaction was a tax free, stock for stock exchange. The total shares issued by ProHealth Medical Technologies, Inc. in that transaction were 11,000,000: 5,500,000 to RHL Management, Inc; and 5,500,000 to Lawrence Lee, the two shareholders of Applied DNA Sciences, Inc. Subsequent to that transaction, RHL Management, Inc. and Lawrence Lee transferred 180,000 and 680,000 shares, respectively, to a company treasury account entitled "Applied DNA Sciences, Inc. Hiring Incentive Treasury Account" which shares are to be used from time to time to entice new management and employees to join the Company. After the aforementioned reorganization was effectuated, the corporate name of ProHealth Medical Technologies, Inc. was changed to Applied DNA, Sciences, Inc. The Reporting Person does not have any present plan or proposal as a stockholder which relates to, or would result in any action with respect to, the matters listed in paragraphs (b) through (j) of Item 4 of Schedule 13D. In the future, the Reporting Person may decide to purchase additional shares of Common Stock in the open market or a private transaction, or to sell any or all of his shares of Common Stock. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. a) As of December 15, 2002, the corporation had issued and outstanding a total of 21,551,640 shares of Common Stock. As of that date, the Reporting Person was the beneficial owner of 4,820,000 shares of Common Stock or 22.4% of the issued and outstanding Common Stock. (b) The Reporting Person has the sole power to vote, or to direct the vote of, 4,820,000 shares of Common Stock and sole power to dispose of, or to direct the disposition of 4,820,000 shares of Common Stock. (c) The Reporting Person initially acquired 5,500,000 shares in a Plan and Agreement of Reorganization under Section 368 (a)(1)B of the Internal Revenue Code between the shareholders of Applied DNA Sciences, Inc. and ProHealth Medical Technologies, Inc. (the former name of the reporting Nevada corporation, Applied DNA Sciences, Inc.) (d) Not applicable. (e) Not applicable. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. Not applicable. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. There are no purchases or sales to disclose at this time. SIGNATURE. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 15, 2003 By: /s/Larry Lee Larry lee -----END PRIVACY-ENHANCED MESSAGE-----